United States: Government Files Statement Of Interest Distinguishing "Caronia" In Off-Label Promotion False Claims Act (FCA) Case

Last Updated: December 3 2013
Article by Toni-Ann Citera
Most Read Contributor in United States, September 2019

On November 7, the U.S. Attorney's Office for the Southern District of New York filed a statement of interest in United States ex rel. Matthew Cestra, et al. v. Cephalon, Inc., et al., 10 Civ. 6457 (SHS) (S.D.N.Y.), in connection with a motion by the defendant pharmaceutical company to dismiss, based in part on the Second Circuit's decision in United States v. Caronia, 703 F.3d 149 (2d Cir. 2012).1 The Government submitted its Statement of Interest "to advise the Court of its position that the Second Circuit's recent decision in Caronia does not preclude a cause of action under the False Claims Act based on a manufacturer's off-label marketing of a prescription drug causing the submission of false claims to federal health care programs."2 The Statement of Interest is the first time the Government has set forth in writing its position in the Second Circuit on the applicability of Caronia to an off-label case under the False Claims Act ("FCA").3

Background

The Relator, who was formerly employed as a senior level manager by Cephalon, alleged that the company promoted two of its drugs, Treanda® and Fentora®, for off-label uses.4 According to the second amended complaint, originally filed on June 24, Treanda® was approved by the FDA only for "second-line" treatment of indolent non-Hodgkin's lymphoma ("iNHL"), which is treatment for patients whose cancer has progressed after use of another chemotherapy regimen.5 Relator alleged that Cephalon improperly marketed the drug for first-line treatment of iNHL.6 In addition, Relator alleged that Fentora®, an opiod approved to treat breakthrough cancer pain, was promoted by Cephalon for use to relieve pain not related to cancer.7 Relator alleged that the off-label promotion caused false claims to be submitted under federal health care programs, including Medicare and Medicaid.8 The United States did not intervene in the case.

On July 31, Cephalon moved to dismiss the second amended complaint on the ground, among others, that the off-label promotion alleged by Relator was protected commercial speech under the First Amendment.9 Cephalon cited Caronia for the proposition that "the simple promotion of a drug's off-label use by pharmaceutical manufacturers and their representatives is protected by the First Amendment."10

Caronia11

Alfred Caronia was a sales representative for Orphan Medical, Inc., which sold Xyrem®, a drug approved by the FDA for treating narcolepsy in certain adults.12 Caronia was allegedly tape-recorded at speaker programs promoting Xyrem® for unapproved uses including insomnia, fibromyalgia, excessive sleepiness, restless leg syndrome, and Parkinson's disease.13 Following a trial, he was convicted of conspiring to introduce a misbranded drug into interstate commerce in violation of the Food, Drug & Cosmetic Act ("FDCA"), 18 U.S.C. § 371 and 21 U.S.C. § 331(a).14

On appeal, Caronia's conviction was vacated by the Second Circuit.15 In so doing, the court stated, "[w]e conclude simply that the government cannot prosecute pharmaceutical manufacturers and their representatives under the FDCA for speech promoting the lawful, off-label use of an FDA-approved drug."16 The court, in reaching this decision, noted, "[w]hile the government and the FDA have construed the FDCA's misbranding provisions to prohibit off-label promotion by pharmaceutical manufacturers ... as we have observed, the FDCA itself does not expressly prohibit or criminalize off-label promotion."17 Thus, the court took issue with the government's interpretation of the FDCA—that the FDCA's misbranding provisions "criminalize the simple promotion of a drug's off-label use by pharmaceutical manufacturers and their representatives"—finding that "such a construction—and a conviction obtained under the government's application of the FDCA—would run afoul of the First Amendment."18

The Government's Statement of Interest

In its Statement of Interest, the Government argues that, unlike in Caronia, the claims in Cephalon do not implicate the First Amendment.19 According to the Government, Caronia is inapposite because "the FCA does not prohibit off-label promotion of prescription drugs; rather, the FCA prohibits conduct that causes the submission of false claims to the Government for payment."20 The Government maintains that First Amendment issues do not arise "in the context of an FCA claim, such as this one, where a defendant causes others to submit false claims for payment to the Government for non-reimbursable prescription drugs."21

The Government maintains that "[f]or FCA cases predicated on off-label drug marketing, the central question is whether the defendant's marketing caused the submission of the claims, i.e., claims for off-label uses that are not covered or reimbursable by federal health care programs.22 In the case of cancer drugs like Treanda®, the Government states, "medically accepted indications include those listed on the FDA-approved label and may also include certain off-label indications supported by a citation in an approved drug compendium if certain other conditions are met."23 "However, when a manufacturer engages in the marketing of drugs for indications that are not FDA approved for that drug or not otherwise supported by a compendium listing, its conduct may cause false non-covered claims to be submitted to federal health care programs, and liability under the FCA may lie."24 Thus, the Government concludes, "the False Claims Act does not on its face create liability for off-label promotion of a drug. Instead the FCA prohibits conduct that knowingly causes the submission of false claims, such as claims for treatments that are not 'reasonable and necessary.'"25

According to the Government, the "FCA does not prohibit speech; rather it is a remedy for actions that cause the submission of a false claim for payment to the Government."26 The Government states that "as a statutory matter, it is irrelevant whether a party causes the submission of a false claim by words, by conduct, or by a combination of both."27

The Government argues that "the fact that a person can knowingly cause the submission of false claims through speech does not suddenly transform this prohibited activity (false claim) into protected speech."28 Citing Jews for Jesus, Inc. v. Jewish Community Relations Council of N.Y., Inc., 968 F.2d 286, 295-96 (2d Cir. 1992), itself quoting Giboney v. Empire Storage & Ice, Co., 336 U.S. 490, 502 (1949), the Government observes that "'[i]t has never been deemed an abridgement of freedom of speech ... to make a course of conduct illegal merely because the conduct was in part initiated, evidenced, or carried out by means of language, either spoken, written, or printed.'"29 The Government states that "[j]ust as the Government may prohibit price-fixing conspiracies under the antitrust laws even when speech is instrumental to the conspiracy, so may the Government prohibit companies from knowingly causing the submission of false claims even when speech is the means by which they cause the false claims to be submitted."30

The Government also notes that Caronia "did not concern false or misleading off-label marketing" and stated that "'to warrant First Amendment protection, the speech in question must not be misleading and must concern lawful activity.'"31 The Government argues that "[t]o the extent that the SAC alleges that Cephalon engaged in false and misleading promotion of the drugs, the Court should reject Cephalon's assertion that its alleged conduct is somehow protected by the First Amendment."32

Implications

The Government's Statement of Interest is consistent with the Government's previous articulations of its views on when and why claims for off-label use are false under the FCA. For example, in United States ex rel. Peter Prevost v. Pfizer, Inc., et al., No. 03-CV-11084-PBS (D. Mass.), the Government stated that a claim for an unapproved use of a drug is false under the FCA when it is not for a "medically-accepted indication." Nevertheless, the Statement of Interest is useful to the pharmaceutical and medical device industries as the first written expression of the Government's position on the applicability of Caronia to off-label FCA cases in the Second circuit and as guidance for the Government's position in future cases.

Footnotes

1. See Statement of Interest of the United States of America ("Statement"). New York State also filed a statement of interest, in which it argued that the "United States' arguments in its Statement of Interest apply with equal force to defeat the contention that Caronia requires dismissal of the NYFCA claims based on a manufacturer's off-label marketing of a prescription drug that causes the submission of false claims to the Medicaid program." See Statement of Interest of Plaintiff the State of New York in Response to Defendant's Motion to Dismiss Relator's Second Amended Complaint.

2. Statement at 1.

3. 31 U.S.C.§§ 3729-3733.

4. See Corrected Second Amended Complaint ("SAC") at ¶¶ 115-190, 291-329.

5. See, e.g., id. at ¶¶ 3, 19, 68-71, 115-90, 291-329 at ¶¶ 68-69.

6. Id. at ¶¶ 68-69; 115-190.

7. Id. at ¶¶ 8-9, 70-71, 291-329.

8. See, e.g., id. at ¶ 378-646.

9. Memorandum in Support of Motion to Dismiss Second Amended Complaint ("Cephalon Br.") at 14-20.

10. Id. at 14 (citing Caronia, 703 F. 3d at 162).

11. Jones Day represented Washington Legal Foundation as Amicus Curiae before the Second Circuit in the Caronia matter.

12. 703 F. 3d at 155-56.

13. Id. at 156-57.

14. Id. at 159.

15. Id. at 169.

16. Id.

17. Id. at 162.

18. Id.

19. Statement at 2.

20. Id.

21. Id.

22. Id. at 4.

23. Id.

24. Id. at 4.

25. Id. at 5.

26. Id.

27. Id. at 6.

28. Id.

29. Id.

30. Id.

31. In its response to the Government's Statement of Interest, Cephalon argues that it is the off-label promotion that is alleged to be the violation. "Applying the FCA under such circumstances, therefore, in this context would amount to penalizing speech. This is precisely the type of content- and speaker-based restriction that requires heightened scrutiny under the First Amendment. Caronia, 703 F.3d at 164-65. 'Speech in aid of pharmaceutical marketing...is a form of expression protected by the Free Speech Clause of the First Amendment.' Sorrell v. IMS Health Inc. 131 S. Ct. 2653, 2659 (2011)."

32. Id. at 6-7.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
Similar Articles
Relevancy Powered by MondaqAI
 
In association with
Related Topics
 
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
 
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Mondaq Free Registration
Gain access to Mondaq global archive of over 375,000 articles covering 200 countries with a personalised News Alert and automatic login on this device.
Mondaq News Alert (some suggested topics and region)
Select Topics
Registration (please scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.

Disclaimer

The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.

General

Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions